Interferon Alpha Lozenges Plus Oseltamivir for Influenza Treatment
Pilot Study of Interferon Alpha Lozenges Plus Oseltamivir in the Treatment of Influenza A Infection
Sponsor: Ainos, Inc. (f/k/a Amarillo Biosciences Inc.
A PHASE2 clinical study on Influenza A Virus Infection, this trial is completed. The trial is conducted by Ainos, Inc. (f/k/a Amarillo Biosciences Inc. and has accumulated 9 data snapshots since 2011. Infectious disease trials contribute critical data for public health response and treatment development.
Status Flow
Change History
9 versions recorded-
Dec 2025 — Present [monthly]
Completed PHASE2
-
Sep 2025 — Dec 2025 [monthly]
Completed PHASE2
-
Sep 2024 — Sep 2025 [monthly]
Completed PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE2
-
Nov 2022 — Jul 2024 [monthly]
Completed PHASE2
▶ Show 4 earlier versions
-
Jan 2021 — Nov 2022 [monthly]
Completed PHASE2
-
Jun 2018 — Jan 2021 [monthly]
Completed PHASE2
-
Feb 2017 — Jun 2018 [monthly]
Completed PHASE2
-
Jan 2017 — Feb 2017 [monthly]
Completed PHASE2
First recorded
Jan 2011
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Ainos, Inc. (f/k/a Amarillo Biosciences Inc.
- CytoPharm, Inc.
For direct contact, visit the study record on ClinicalTrials.gov .